Loading clinical trials…
Loading clinical trials…
Clinical trials · failure tracking
Oncology studies whose overall status is TERMINATED, WITHDRAWN or SUSPENDED on ClinicalTrials.gov, with the stop reason exactly as the registrant posted it. A category is attached only when an explicit keyword rule matches the text; CancerIndex never infers why a study stopped.
826 stopped studies mapped to Malignant Female Reproductive System Neoplasm and descendants · 86% state a reason
Over the 826 studies matching the cancer, status and year filters (the category filter does not change this chart). Each study is counted once, in the first matching category; greyed bars are studies whose text matched no rule or was empty.
Computedrules ci-stop-reasons-v1 · keyword matching only
A category is assigned when one of its keywords appears in the posted text (case-insensitive, whole words). Rules are tested in this order and the first match wins; every match is kept in the API (reasonMatches).
| NCT | Title | Phase | Status | First posted | Lead sponsor | Why stopped (as posted) | Category |
|---|---|---|---|---|---|---|---|
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or… | Phase 2 | terminated | Aug 1, 2018 | M.D. Anderson Cancer Center | Lack of Efficacy | Efficacy / futility |
| NCT05179239 | A Study of SHR-1701 Plus Platinum-containing Chemotherapy With or Without BP102… | Phase 3 | terminated | Jan 5, 2022 | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | Sponsor develops strategy adjustment | Sponsor / business decision |
| NCT04067544 | Acupuncture Treatment of Chemotherapy-Induced Peripheral Neuropathy in Women | N/A | terminated | Aug 26, 2019 | University of Utah | Unforeseen complications due to COVID-19 and funding | COVID-19 / pandemic |
| NCT05126342 | Study to Estimate Efficacy of Combining Dostarlimab and Niraparib in Relapsed EOC After… | Phase 2 | withdrawn | Nov 19, 2021 | AGO Research GmbH | Study has been withdrawn; was never submitted to Competent authority nor to ethics commitee. | Other (stated, no rule matched) |
| NCT03527264 | BrUOG 355: Nivolumab to Tailored Radiation Therapy With Concomitant Cisplatin in the… | Phase 2 | terminated | May 17, 2018 | Brown University | Slow enrollment | Enrollment / accrual |
| NCT04383210 | Study of Seribantumab in Adult Patients With NRG1 Gene Fusion Positive Advanced Solid… | Phase 2 | terminated | May 12, 2020 | Elevation Oncology | Business decision | Sponsor / business decision |
| NCT03829501 | A Phase 1/2, Open-label, Multi-center Study of the Safety and Efficacy of Alomfilimab… | Phase 1 / Phase 2 | terminated | Feb 4, 2019 | Kymab Limited | Early discontinuation based on strategic sponsor decision not driven by any safety concerns. | Safety / toxicity |
| NCT06385548 | Efficacy and Safety Study of Lurbinectedin and Dostarlimab in Cancer Patients: Protocol…(LiDer) | Phase 1 / Phase 2 | withdrawn | Apr 26, 2024 | Vall d'Hebron Institute of Oncology | IMP owner decision | Other (stated, no rule matched) |
| NCT05192850 | Endometrial Cancer Recurrence in Patients Taking Metformin | — | withdrawn | Jan 14, 2022 | WellSpan Health | study was not started at WellSpan | Other (stated, no rule matched) |
| NCT03585764 | MOv19-BBz CAR T Cells in aFR Expressing Recurrent High Grade Serous Ovarian, Fallopian… | Phase 1 | terminated | Jul 13, 2018 | University of Pennsylvania | This study was halted prematurely due to recruitment barriers | Enrollment / accrual |
| NCT02641639 | FOCUS: PCC + Bevacizumab + CA4P Versus PCC + Bevacizumab + Placebo for Subjects With… | Phase 2 / Phase 3 | terminated | Dec 29, 2015 | Mateon Therapeutics | The study was terminated early due to the lack of efficacy and the study sponsor's decision to no… | Efficacy / futility |
| NCT03164980 | QoL-Comparison Between Trabectedin/PLD and Pt-based Therapy in Patients With Pt-sensitive…(COMPASS) | Phase 4 | terminated | May 24, 2017 | North Eastern German Society of Gynaecological Oncology | A total of 204 patients were planned to be randomized. Due to slow recruitment of the trial, the… | Enrollment / accrual |
| NCT04889495 | A Post-marketing Surveillance to Assess the Safety and Effectiveness of Zirabev in… | — | withdrawn | May 17, 2021 | Pfizer | The study was withdrawn due to global supply chain issue. Zirabev was not launching in Korea. | Drug supply |
| NCT06257758 | A Phase 1/2 Study of VIO-01 in Participants With Recurrent Solid Tumors | Phase 1 / Phase 2 | terminated | Feb 14, 2024 | Valerio Therapeutics | Business decision | Sponsor / business decision |
| NCT04421547 | Efficacy of Letrozole in Recurrent Ovarian Cancer(MITO32) | Phase 3 | terminated | Jun 9, 2020 | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Logistical problems impacting the speed of enrolment | Enrollment / accrual |
| NCT05470309 | Community Outreach-based Study to Increase Cervical Cancer Screening Among Hispanic Women… | — | withdrawn | Jul 22, 2022 | MetroHealth Medical Center | Personnel departure. | Other (stated, no rule matched) |
| NCT05714306 | PEP-DC and OC-DC Vaccine in High Grade Serous Ovarian Carcinoma(CHUV-OVACURE) | Phase 1 / Phase 2 | withdrawn | Feb 6, 2023 | Centre Hospitalier Universitaire Vaudois | Lack of funding | Funding |
| NCT04750941 | Study of Copanlisib and Ketogenic Diet | Phase 2 | terminated | Feb 11, 2021 | Columbia University | Enrollment challenges | Enrollment / accrual |
| NCT03197584 | QUILT-3.051: NANT Ovarian Cancer Vaccine: Combination Immunotherapy in Subjects With… | Phase 1 / Phase 2 | withdrawn | Jun 23, 2017 | ImmunityBio, Inc. | Trial not initiated | Other (stated, no rule matched) |
| NCT04213794 | Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for…(TOASTIT) | Early Phase 1 | terminated | Dec 30, 2019 | Mayo Clinic | slow accrual | Enrollment / accrual |
| NCT04906382 | Tislelizumab for the Treatment of Recurrent Mismatch Repair Deficient Endometrial Cancer | Early Phase 1 | terminated | May 28, 2021 | Floor Backes, MD | Sponsor reorganization | Other (stated, no rule matched) |
| NCT03632798 | Avastin Plus Chemotherapy vs. Avastin Plus Chemotherapy Guided by Cancer Stem Cell Test…(ACSCO) | Phase 3 | withdrawn | Aug 15, 2018 | Cordgenics, LLC | Slow enrollment | Enrollment / accrual |
| NCT06120972 | Upfront Maintenance Olaparib in Advanced Ovarian Cancer BRCAwt Patients With Known… | Phase 2 | withdrawn | Nov 7, 2023 | Alexander B Olawaiye, MD | Sponsor terminated due to Olaparib losing patent | Other (stated, no rule matched) |
| NCT04254107 | A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer | Phase 1 | terminated | Feb 5, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT04665921 | A Study of SGN-STNV in Advanced Solid Tumors | Phase 1 | terminated | Dec 14, 2020 | Seagen Inc. | Study closed due to portfolio prioritization | Sponsor / business decision |
| NCT03891576 | Newton Study (NEW Dosing MainTenance Therapy Ovarian CaNcer)(Newton) | Phase 2 | terminated | Mar 27, 2019 | Mario Negri Institute for Pharmacological Research | Low accrual rate | Enrollment / accrual |
| NCT06681870 | A Study of ASP1893 in Adults With Advanced CLDN6-positive Solid Tumors | Phase 1 | withdrawn | Nov 8, 2024 | Astellas Pharma Global Development, Inc. | A business decision was made to not initiate this study. | Sponsor / business decision |
| NCT05145569 | Antitumor Activity of Neoadjuvant Chemotherapy with or Without HCW9218 in Metastatic… | Phase 2 | withdrawn | Dec 6, 2021 | Haider Mahdi | Per PI and agent sponsor | Other (stated, no rule matched) |
| NCT04072406 | A Self-Directed Mindfulness Meditation Intervention in Gynecologic Cancer Patients | N/A | terminated | Aug 28, 2019 | Washington University School of Medicine | Covid-19 | COVID-19 / pandemic |
| NCT06752135 | Node Positive Cervical Cancer Treated by Neoadjuvant Chemotherapy Plus Radical Surgery: a…(HRCC1) | — | terminated | Dec 30, 2024 | Azienda Policlinico Umberto I | Retrospectively data collection complited | Other (stated, no rule matched) |
| NCT03099499 | Single Agent ONC201 in Recurrent or Metastatic Endometrial Cancer | Phase 2 | terminated | Apr 4, 2017 | Fox Chase Cancer Center | Slow accrual | Enrollment / accrual |
| NCT05500508 | Oral AMXT 1501 Dicaprate in Combination With IV DFMO | Phase 1 / Phase 2 | terminated | Aug 15, 2022 | Aminex Therapeutics, Inc. | Required re-formulation of DFMO from IV to capsule to maintain safety | Safety / toxicity |
| NCT05289648 | Niraparib in High-grade Endometrial Cancer Trial(NIREC) | Early Phase 1 | withdrawn | Mar 21, 2022 | Sir Mortimer B. Davis - Jewish General Hospital | Unable to obtain funding | Funding |
| NCT03118037 | Transcervical Radiofrequency Ablation of Uterine Fibroids Global Registry(SAGE) | — | terminated | Apr 18, 2017 | Gynesonics | Termination due to continued lack of patient compliance | Other (stated, no rule matched) |
| NCT03549000 | A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in… | Phase 1 | terminated | Jun 7, 2018 | Novartis Pharmaceuticals | After review of data which showed low likelihood of efficacy in these patients Novartis decided to… | Safety / toxicity |
| NCT04939701 | Study of ASP0739 Alone and With Pembrolizumab in Advanced Solid Tumors With NY-ESO-1… | Phase 1 / Phase 2 | terminated | Jun 25, 2021 | Astellas Pharma Global Development, Inc. | The comprehensive assessment of other studies indicated the lack of significant monotherapy… | Other (stated, no rule matched) |
| NCT04826198 | Safety and Efficacy of AsiDNATM, a DNA Repair Inhibitor, Administered Intravenously in…(REVOCAN) | Phase 1 / Phase 2 | terminated | Apr 1, 2021 | Gustave Roussy, Cancer Campus, Grand Paris | Treatment availability issue: The manufacturer of AsiDNA™ decided to cease production to develop an… | Drug supply |
| NCT04530019 | Brachytherapy Innovations in Gynecologic Cancer | — | withdrawn | Aug 28, 2020 | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | The study never opened. | Other (stated, no rule matched) |
| NCT04985357 | Defining the Clinical Potential of Mass Response As a Biomarker for Patient Tumor… | — | withdrawn | Aug 2, 2021 | Travera Inc | Abandoned prior to launch. | Other (stated, no rule matched) |
| NCT03514121 | FPA150 in Patients With Advanced Solid Tumors(FPA150-001) | Early Phase 1 | terminated | May 2, 2018 | Five Prime Therapeutics, Inc. | The Sponsor terminated the study for reasons unrelated to safety. | Safety / toxicity |
| NCT05261490 | Study of Maplirpacept (PF-07901801) in Combination With PLD in Patients With… | Phase 1 / Phase 2 | terminated | Mar 2, 2022 | Pfizer | A business decision was made by Pfizer to terminate and remove the Phase 2 expansion of this study… | Safety / toxicity |
| NCT04493619 | PLX2853 as a Single Agent in Advanced Gynecological Malignancies and in Combination With… | Phase 1 / Phase 2 | terminated | Jul 30, 2020 | Opna Bio LLC | study terminated due to business realignment | Sponsor / business decision |
| NCT06034860 | Study of MT-8421 as Monotherapy and in Combination With Nivolumab in Patients With… | Phase 1 | terminated | Sep 13, 2023 | Molecular Templates, Inc. | Sponsor Termination | Other (stated, no rule matched) |
| NCT02470585 | Veliparib With Carboplatin and Paclitaxel and as Continuation Maintenance Therapy in…(VELIA) | Phase 3 | terminated | Jun 12, 2015 | AbbVie | Business decision not related to patient safety | Safety / toxicity |
| NCT03240523 | A Study to Assess Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids(ASTEROID 5) | Phase 3 | terminated | Aug 7, 2017 | Bayer | Due to a change in the development program, the study was closed prematurely. | Other (stated, no rule matched) |
| NCT05012397 | Milademetan in Advanced/Metastatic Solid Tumors | Phase 2 | terminated | Aug 19, 2021 | Rain Oncology Inc | Sponsor Decision | Sponsor / business decision |
| NCT03238053 | Laser Treatment of Genito-urinary Syndrome in Women | N/A | withdrawn | Aug 3, 2017 | Herning Hospital | Hospital terminated treatment with laser | Other (stated, no rule matched) |
| NCT04923672 | Exercise Preconditioning with Cancer Surgeries(ExPre 01) | N/A | terminated | Jun 11, 2021 | University of Virginia | Company providing the computer application for exercise intervention suddenly closed for business | Sponsor / business decision |
| NCT06161493 | ZEN003694 Combined With Niraparib in Patients With Metastatic or Recurrent Solid Tumors | Phase 1 | withdrawn | Dec 8, 2023 | Haider Mahdi | Investigator Discretion | Investigator |
| NCT03677024 | Evaluation of the Efficacy for Sentinel Lymph Node Policy in Intermediate-risk… | N/A | withdrawn | Sep 19, 2018 | Fudan University | This study was not approved by the Ethics Committee | Other (stated, no rule matched) |
Stop reasons are registrant-reported free text and are displayed verbatim (truncated; hover for the full text). Categories come from explicit keyword rules and are never inferred from the study design, sponsor or outcome; a study that stopped for several reasons is filed under the first rule that matched. A TERMINATED status does not imply a negative result.
Data updated 23 days agoSource updated Apr 17, 2025source: clinicaltrials